Iridex
Iridex provides an array of established laser procedures that expand ways to manage, preserve, and prolong vision.
Iridex provides an array of established laser procedures that expand ways to manage, preserve, and prolong vision.
Iridex provides an array of established laser procedures that expand ways to manage, preserve, and prolong vision.
Iridex is a worldwide leader in developing and manufacturing innovative and versatile light-based medical systems and delivery devices to treat glaucoma and retinal diseases. With a deep commitment to customer success, they offer comprehensive technical, clinical, and service support programs, maintaining a standard of excellence and superior technology for superior results.
Their products are sold in the United States and Germany through a direct sales force and in over 100 countries through a network of approximately 70 independent distributors. Some of their products include the Cyclo G6 glaucoma laser, IQ 577 retinal laser, IQ 532 retinal laser, and TxCell scanning laser delivery device. Learn more at iridex.com.
Founded in 1989, the company operates in the Biotechnology, Health Care, and Manufacturing industries. Their last Venture Round investment was on 01 January 1991, with participation from New Enterprise Associates.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Jan 1991 |
No recent news or press coverage available for Iridex.
We care about your data, and we'd love to use cookies make your experience better.